<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00211900</url>
  </required_header>
  <id_info>
    <org_study_id>Nabi-1367</org_study_id>
    <nct_id>NCT00211900</nct_id>
  </id_info>
  <brief_title>Evaluation of Manufacturing Lot of StaphVAX</brief_title>
  <official_title>A Phase 3, Multicenter, Open-Label, Historical Comparative Study to Evaluate Immunogenicity and Safety of a Commercial Lot of StaphVAX®, a Bivalent Staphylococcus Aureus Glycoconjugate Vaccine in Adults on Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nabi Biopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nabi Biopharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study answers a U.S. Food and Drug Administration requirement for evaluation in people
      of a manufacturing lot of vaccine. Subjects receive one dose of one lot of vaccine. The
      antibodies in the blood measure the immunogenicity of the vaccine, and typical vaccine safety
      information is also collected.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Type-specific antibody concentrations</measure>
    <time_frame>6 weeks after vaccine dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Type-specific antibody concentrations</measure>
    <time_frame>3 weeks after vaccine dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elicited vaccine reactogenicity.</measure>
    <time_frame>daily for 7 days after dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Staphylococcal Infections</condition>
  <condition>Chronic Kidney Failure</condition>
  <arm_group>
    <arm_group_label>vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of StaphVAX in hemodialysis patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>S. aureus Type 5 &amp; 8 Capsular Polysaccharide Vaccine</intervention_name>
    <description>single IM dose totalling 200 mcg of conjugate</description>
    <arm_group_label>vaccine</arm_group_label>
    <other_name>StaphVAX®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  8 wk of hemodialysis for ESRD,

          -  have written informed consent,

          -  a negative serum pregnancy test if appropriate,

          -  and expect to comply with protocol procedures and schedule

        Exclusion Criteria:

          -  known HIV,

          -  immunomodulatory drugs,

          -  malignancy (other than basal cell or squamous cell carcinoma, carcinoma in situ of the
             cervix, or early stage prostate cancer),

          -  active infection in the 2 weeks prior to study injection,

          -  serious S. aureus infection within the last 3 months prior to injection,

          -  use of investigational drugs, vaccines or devices within the prior 30 days,

          -  hypersensitivity to components of StaphVAX
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matt Hohenboken, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Nabi Biopharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Trialogic Research</name>
      <address>
        <city>Madison</city>
        <state>Alabama</state>
        <zip>35758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>December 26, 2007</last_update_submitted>
  <last_update_submitted_qc>December 26, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2008</last_update_posted>
  <responsible_party>
    <name_title>Matt Hohenboken, MD, PhD, Executive Director, Clinical &amp; Medical Affairs</name_title>
    <organization>Nabi Biopharmaceuticals</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

